Apollo signs $500,000 deal with Symansis
Wednesday, 11 June, 2008
Suspended Sydney biotech Apollo Life Sciences (ASX: AOP) has sold a proportion of its non-core assets to New Zealand antibody specialist Symansis for $500,000.
The parties have also signed a short-term supply contract.
The deal also allows Symansis to license some of Apollo's proprietary techniques to assist in the manufacture of proteins for sale as research reagents.
The parties have also entered into a supply contract, whereby Apollo has also agreed to manufacture and supply specified proteins to Symansis.
In a statement, Apollo's CEO John Priest said the company is currently consolidating its operations and intends to focus on its core research activities, including its oral and transdermal delivery sytems and its portfolio of human-expressed proteins.
RSV immunisation program for babies slashes hospital stays
An Australian-first study has demonstrated the effectiveness of immunisation against respiratory...
A targeted treatment option for psoriasis
New research from MedUni Vienna paves the way for the development of a therapy that not only...
Maternal cannabis use puts kids at risk of behavioural problems
Children exposed to their mother's cannabis use during pregnancy and after birth are three...
